Lv5
900 积分 2023-06-12 加入
NSCLC: Five trials to watch
4天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression The BRIGHT-2 Phase 3 Randomized Clinical Trial
1个月前
已关闭
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma?
1个月前
已关闭
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
1个月前
已完结
Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better?
1个月前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer A Randomized Clinical Trial
1个月前
已关闭
Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer
2个月前
已关闭
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
2个月前
已关闭
皖公网安备34019202002308
